Lupus & antiphospholipid syndrome
Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study
- terminated early after planned futility analysis
- Both studies terminated early following a planned futility analysis in the core study
Authors' conclusion
Secukinumab did not demonstrate superior efficacy over placebo in patients with active LN. Secukinumab was well-tolerated with no new or unexpected safety signals detected.
Study context
- Population
- Adult patients with active LN
- Comparison
- Secukinumab 300 mg s.c. plus standard of care (SoC) vs placebo plus SoC
- Primary endpoint
- Proportion of patients achieving complete renal response (CRR)
- Follow-up
- Week 52
Methodological detailsphase III, double-blind, placebo-controlled, open-label extension study
- Phase III
- Double-blind
- Placebo-controlled
- Open-label extension study
Primary result
As reported in the abstract
CRR
Secondary outcomes
Secondary end points of the core study
- No differences between secukinumab and placebo in any secondary end point
Open-label extension study
- Results not interpretable owing to low patient number in data analysis
- n = 31
Safety
Treatment-emergent adverse events
- Incidence comparable between secukinumab and placebo
Original publication
Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study. Rheumatology (Oxford). Published 15 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →